Zacks Research Has Bullish Forecast for ALLO Q1 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a research note issued to investors on Wednesday, April 2nd. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of ($0.31) for the quarter, up from their previous estimate of ($0.37). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.26) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.40) EPS.

Several other research analysts have also issued reports on the stock. Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Friday, March 14th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. HC Wainwright decreased their price target on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, March 19th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.29.

Allogene Therapeutics Stock Performance

NASDAQ:ALLO opened at $1.44 on Monday. The company has a 50-day moving average of $1.81 and a 200-day moving average of $2.19. Allogene Therapeutics has a 52 week low of $1.30 and a 52 week high of $4.25. The company has a market capitalization of $312.86 million, a price-to-earnings ratio of -0.92 and a beta of 0.99.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06.

Insiders Place Their Bets

In other Allogene Therapeutics news, insider Timothy L. Moore sold 14,746 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the sale, the insider now owns 250,713 shares in the company, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO David D. Chang sold 46,668 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $1.96, for a total transaction of $91,469.28. Following the transaction, the chief executive officer now owns 5,276,569 shares in the company, valued at $10,342,075.24. The trade was a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 104,866 shares of company stock valued at $194,461. 24.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Allogene Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Lynx1 Capital Management LP boosted its holdings in Allogene Therapeutics by 75.3% in the fourth quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company’s stock valued at $23,163,000 after acquiring an additional 4,672,349 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Allogene Therapeutics by 30.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company’s stock valued at $7,586,000 after purchasing an additional 831,146 shares during the period. Foresite Capital Management VI LLC bought a new position in shares of Allogene Therapeutics in the 4th quarter valued at about $7,345,000. Geode Capital Management LLC grew its position in shares of Allogene Therapeutics by 14.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after buying an additional 407,070 shares during the period. Finally, Two Sigma Advisers LP grew its position in shares of Allogene Therapeutics by 12.1% during the 4th quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company’s stock worth $5,756,000 after buying an additional 291,800 shares during the period. 83.63% of the stock is owned by institutional investors and hedge funds.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).